The effect of enrofloxacin on cell proliferation and proteoglycans in horse tendon cells.
Fluoroquinolone antibiotics have been used widely in humans and domestic animals, including horses, because of their broad-spectrum bactericidal activity, and relative safety. The use of fluoroquinolones, however, is not without risk. Tendonitis and spontaneous tendon rupture have been reported in people during or following therapy with fluoroquinolones. We have studied the effects of enrofloxacin, a fluoroquinolone antibiotic used commonly in domestic animals, on tendon cell cultures established from equine superficial digital flexor tendons. Effects on cell proliferation and morphology were studied using cell counting and scanning electron microscopy. Monosaccharide content and composition was determined by gas chromatography-mass spectrometry analysis. Western and Northern blot analyses were utilized to evaluate the synthesis and expression of two proteoglycans, biglycan and decorin. Our data demonstrate that enrofloxacin inhibits cell proliferation, induces morphological changes, decreases total monosacharide content and alters small proteoglycan synthesis at the glycosylation level in equine tendon cell cultures. These effects are more pronounced in juvenile tendon cells than in adult equine tendon cells. We hypothesize that morphological changes and inhibition of cell proliferation are a result of impaired production of biglycan and decorin, proteoglycans involved in fibrillogenesis of collagen, the most important structural component of the tendon of enrofloxacin-treated tendon cells. Our findings suggest that fluoroquinolones should be used with caution in horses, especially in foals.
Yoon
J H
JH
The Soft Tissue Center, Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7388, USA.
Brooks
R L
RL
Khan
A
A
Pan
H
H
Bryan
J
J
Zhang
J
J
Budsberg
S C
SC
Mueller
P O E
PO
Halper
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D017209:Apoptosis; D058578:Biglycan; D015152:Blotting, Northern; D015153:Blotting, Western; D002241:Carbohydrates / Q000737:chemistry; D002455:Cell Division / Q000187:drug effects; D002849:Chromatography, Gas; D058575:Decorin; D004591:Electrophoresis, Polyacrylamide Gel; D000077422:Enrofloxacin; D016326:Extracellular Matrix Proteins; D024841:Fluoroquinolones / Q000633:toxicity*; D006736:Horses; D013058:Mass Spectrometry; D008855:Microscopy, Electron, Scanning; D011509:Proteoglycans / Q000737:chemistry / Q000378:metabolism; D015363:Quinolones / Q000633:toxicity*; D012313:RNA / Q000737:chemistry; D013710:Tendons / Q000187:drug effects*; D013997:Time Factors
D000970:Antineoplastic Agents; C546884:BGN protein, human; D058578:Biglycan; D002241:Carbohydrates; C546878:DCN protein, human; D058575:Decorin; D016326:Extracellular Matrix Proteins; D024841:Fluoroquinolones; D011509:Proteoglycans; D015363:Quinolones; D000077422:Enrofloxacin; D012313:RNA